Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nrx Pharmaceuticals Inc (NQ: NRXP )

1.290 +0.020 (+1.57%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nrx Pharmaceuticals Inc

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
NRx Pharma's COVID-19 Vaccine Candidate Show Potential Against Omicron Variant
NRx Pharmaceuticals (NASDAQ: NRXP) has received scientific evidence from the Israel Institute for Biological Research (IIBR) that the BriLife vaccine can  
Via Benzinga
Investor Action Reminder: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NRx Pharmaceuticals, Inc. (NRXP)
From Law Offices of Howard G. Smith
Via Business Wire
The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
NRx Receives Initial Report of Patient Safety From 'Right To Try' Use Of Zyesami For COVID-19
NRx Pharmaceuticals (NASDAQ: NRXP) has  
Via Benzinga
Shareholder Action Notice: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of NRx Pharmaceuticals, Inc. (NRXP) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Shareholder Action Alert: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of NRx Pharmaceuticals, Inc. (NRXP) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Shareholder Alert: Robbins LLP Reminds Investors that NRx Pharmaceuticals, Inc. (NRXP) is Being Sued for Misleading Shareholders
From Robbins LLP
Via Business Wire
Investor Action Reminder: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles - (NewMediaWire) - January 21, 2022 - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NRx Pharmaceuticals, Inc.... 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of NRx Pharmaceuticals, Inc. (NRXP) Investors
From Law Offices of Howard G. Smith
Via Business Wire
Shareholder Action Notice: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of NRx Pharmaceuticals, Inc. (NRXP) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Shareholder Alert: Robbins LLP Informs Investors that NRx Pharmaceuticals, Inc. (NRXP) is Being Sued for Misleading Shareholders
From Robbins LLP
Via Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of NRx Pharmaceuticals, Inc. (NRXP) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
ALERT: NRx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NRXP; NRXPW
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
NRX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against NRx Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of NRx Pharmaceuticals, Inc. (NRXP) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
NRXP EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages NRx Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – NRXP; NRXPW
From Rosen Law Firm
Via Business Wire
NRx Pharma's Zyesami Access Expanded To COVID-19 Patients Who Exhausted All Approved Treatments
NRx Pharmaceuticals (NASDAQ: NRXP) has announced enhancements to its Expanded Access and Right to Try programs. The programs enable patients to receive Zyesami (... 
Via Benzinga
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio... 
Via Benzinga
NRx Pharma Files Counterclaim Against Relief Therapeutics Over COVID-19 Candidate Rights
NRx Pharmaceuticals Inc (NASDAQ: NRXP) has filed a counterclaim against its former partner, Relief Therapeutics Holdings (OTC: RLFTF), in an ongoing... 
Via Benzinga
20 Stocks Moving in Monday's Pre-Market Session
Gainers Bone Biologics Corporation (NASDAQ: BBLG) rose 32.1% to $4.53 in pre-market trading. Pluristem Therapeutics Inc. (NASDAQ: PSTI) rose 28.5% to $1.89 in pre-... 
Via Benzinga
DTST Stock Alert: The Pro Sports Deal That Has Data Storage Shares Soaring Today
Data Storage (DTST) stock is soaring higher on Wednesday after announcing a massive deal with an unnamed sports team in the U.S. 
Via InvestorPlace
WEJO Stock: 9 Things to Know About Wejo Group as Microsoft Deal Shines Light on the AV Player
Wejo Group (WEJO) stock is rising higher on Wednesday after announcing a deal with Microsoft for a vehicle data platform. 
Via InvestorPlace
NRXP Stock Alert: The Covid-19 News Lifting NRx Pharmaceuticals Today
News of a potential Covid-19 treatment breakthrough has NRXP stock rising today. Here's what you need to know about this FDA filing. 
Via InvestorPlace
RLFTF Stock Alert: What Is Going on With Relief Therapeutics Today?
RLFTF stock and NRXP stock are both gaining this morning after NRx Pharmaceuticals filed for emergency use for its Covid-19 treatment. 
Via InvestorPlace
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.